# Gilteritinib for the Treatment of ALK NSCLC

> **NCT06225427** · PHASE1 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography
- **DRUG:** Gilteritinib
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06225427
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225427, "Gilteritinib for the Treatment of ALK NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06225427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*